Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

IMPORTANCE: Patients with oligometastatic non–small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for the use of immunotherapy e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Oncol
Hauptverfasser: Bauml, Joshua M., Mick, Rosemarie, Ciunci, Christine, Aggarwal, Charu, Davis, Christiana, Evans, Tracey, Deshpande, Charuhas, Miller, Linda, Patel, Pooja, Alley, Evan, Knepley, Christina, Mutale, Faith, Cohen, Roger B., Langer, Corey J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2019
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624820/
https://ncbi.nlm.nih.gov/pubmed/31294762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1449
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge